Introduction {#Sec1}
============

L-arginine (ARG) is a semi-essential amino acid that is important for medicinal and industrial applications. ARG is known to stimulate secretion of growth hormones \[[@CR1]\], prolactin \[[@CR2]\], insulin \[[@CR3]\] and glucagon \[[@CR4]\], promote muscle mass \[[@CR5]\], enhance wound healing \[[@CR6]\] and as a precursor for nitric oxide \[[@CR7]\]. Physiological importance of ARG supplementation is further raised by the important roles of nitric oxide in cardiovascular and neurological systems \[[@CR8]\]. For many important applications of ARG, its industrial level production has become an important task. It can be produced by microbial fermentation at an industrial scale \[[@CR9]\] as for other amino acids such as L-glutamate (GLU) \[[@CR10]\], L-lysine (LYS) \[[@CR11]\], L-tryptophan (TRP) \[[@CR12]\], L-valine (VAL) \[[@CR13]\], L-threonine (THR) \[[@CR14]\] and L-alanine (ALA) \[[@CR15]\]. For these amino acids, model organisms such as *Corynebacterium glutamicum* \[[@CR16]\] and *Escherichia coli* \[[@CR17]\] have been widely used as production hosts, while ARG production has been performed using *B. subtilis* \[[@CR18]\] and *C. glutamicum* \[[@CR9]\]. It has been almost six decades since ARG production has been explored and studied using microorganisms. As in the cases for other amino acid production, random mutagenesis has been used in order to obtain efficient producer strains \[[@CR19]\]. However, random mutagenesis is problematic due to the unwanted genomic changes introduced. Thus, much effort has been exerted to develop strains through metabolic engineering.

Systems metabolic engineering now allows construction of efficiently performing cell-factories for the microbial production of not only amino acids but also bio-fuels \[[@CR20]\],\[[@CR21]\], pharmaceuticals \[[@CR22]\], bio-plastics \[[@CR23]\], platform chemicals \[[@CR24]\]-\[[@CR26]\] and even silk proteins \[[@CR27]\]. It is powered by rapidly advancing tools and continuously accumulating genetic and molecular information. It also aims to develop strains based on optimization of the entire bioprocess from strain design to industrial level cultivation. Its strategies include deletion of competing pathways \[[@CR28]\], strengthening upstream pathways for increasing precursor pool \[[@CR11]\], engineering transporters \[[@CR29]\] and fine-tuning expression levels \[[@CR30]\]. Systems metabolic engineering approach has been successfully applied in order to rationally design ARG producer strain for the efficient industrial level production which can be potentially engineered to produce ARG derivatives as well \[[@CR9]\].

Systems metabolic engineering strategies can also be used for producing ARG-related compounds, such as L-ornithine (ORN), putrescine, and cyanophycin that share common pathways. ORN is a non-proteinogenic amino acid that has shown to improve athletic performance along with ARG and L-citrulline (CIT), another intermediate metabolite in the ARG biosynthetic pathway \[[@CR31]\]. Putrescine is a four-carbon diamine platform chemical that can be incorporated into various polymers such as nylon-4,6 and nylon-4,10. Cyanophycin can be used to produce polyaspartate which is another bio-polymer for various technical applications. However, efficient metabolic engineering for such compounds has been limited by incomplete understanding on ARG biosynthesis even with the publically available genome sequences \[[@CR32]\]. Here, we review the three major pathways for ARG biosynthesis in prokaryotes including the recent discoveries. We also discuss various strategies applied to engineer strains for the efficient production of ARG, ORN, putrescine and cyanophycin using recently established examples.

L-Arginine biosynthetic pathway and its regulation {#Sec2}
--------------------------------------------------

In prokaryotes, there are three major biosynthetic pathways for ARG; "linear", "recycling" and the "new" pathways (Figure [1](#Fig1){ref-type="fig"}) \[[@CR33]\],\[[@CR34]\]. Each pathway is comprised of eight enzymatic steps from GLU and the major differences in these pathways are in that different genes are involved for conversion of *N*-acetylornithine (Ac-ORN) for further downstream reactions toward ARG \[[@CR35]\]. In the linear pathway (Figure [1](#Fig1){ref-type="fig"}A), Ac-ORN is converted to ORN by acetylornithinase (AOase; encoded by *argE*) \[[@CR36]\], whereas in the recycling pathway (Figure [1](#Fig1){ref-type="fig"}B) this is catalyzed by a different enzyme, ornithine acetyltransferase (OATase; encoded by *argJ*) \[[@CR37]\]. In the third pathway, which has not been named, ORN is bypassed and instead *N*-acetylcitrulline (Ac-CIT) is formed by acetylornithine carbamoyltransferase (AOTCase; encoded by *argF'*, Figure [1](#Fig1){ref-type="fig"}C) \[[@CR38]\]. While certain aspects of the pathway components are still under debate, they are undoubtedly important in ARG biosynthesis and metabolic engineering purposes.Figure 1**Representative ARG biosynthesis routes in prokaryotes. (A)** The linear pathway, **(B)** the recycling pathway and **(C)** the newly discovered pathway for the ARG biosynthesis are shown. Dashed line indicates feedback inhibition by ARG on the first (NAGS) **(A)** and second (NAKG) **(B)** committed steps in the pathways. Blue arrows indicate *argE* used in the linear pathway **(A)**. Orange arrows indicate *argJ* used in the recycling pathway **(B)**. Green arrow indicates *argF'* used in the newly found pathway **(C)**. ARG catabolic pathways are also shown. Ac-GLU, *N*-acetylglutamate; Ac-GLU-P, *N*-acetylglutamyl-5-phosphate; Ac-GLU-SA, *N*-acetylglutmate-5-semialdehyde; ARG-Suc, L-argininosuccinate; GLU-SA, L-glutamate-5-semialdehyde; P5C, 1-pyrroline-5-carboxylate. The asterisk indicates putative NAGS that has not been characterized in many organisms.

In the linear pathway (Figure [1](#Fig1){ref-type="fig"}A), GLU is converted to acetylglutamate (Ac-GLU) by *N*-acetylglutamate synthase (NAGS, encoded by *argA*) which is inhibited by ARG through negative feedback regulation \[[@CR36]\],\[[@CR39]\]. Sequential catalytic reactions catalyzed by the next three enzymes, *N*-acetylglutamate kinase (NAGK, encoded by *argB*), *N*-acetylglutamate semialdehyde dehydrogenase (encoded by *argC*) and *N*-acetylornithine transaminase (encoded by *argD*), which are common in the three pathways (Figure [1](#Fig1){ref-type="fig"}), yield *N*-acetylornithine (Ac-ORN) \[[@CR34]\]. The next step, which distinguishes the linear pathway from the other two pathways, is deacetylation of Ac-ORN by AOase to yield ORN \[[@CR40]\],\[[@CR41]\]. The next and final steps are carried out by ornithine carbamoyltransferase (OTC or OTCase, encoded by *argF*), argininosuccinate synthase (encoded by *argG*) and argininosuccinate lyase (encoded by *argH*), which finally yield ARG \[[@CR35]\]. This pathway has been found in a few species such as *Myxococcus xanthus* \[[@CR41]\] and *E. coli* \[[@CR36]\].

In many other prokaryotes including *Geobacillus stearothermophilus* (formerly *Bacillus stearothermophilus*) \[[@CR37]\],\[[@CR42]\],\[[@CR43]\], *Thermotoga neapolitana* \[[@CR42]\], Pseudomonads \[[@CR44]\], *Neisseria gonorrhoeae* \[[@CR45]\] *Streptomyces coelicolor* \[[@CR46]\] and *C. glutamicum* (formerly *Micrococcus glutamicus*) \[[@CR19]\],\[[@CR47]\], ARG is synthesized *via* the recycling pathway and many aspects remain unknown herein (Figure [1](#Fig1){ref-type="fig"}B). The recycling pathway is regarded as more evolved and economical than the linear pathway and is "recycling" in the sense that the acetyl group deacetylated from Ac-ORN in the fifth biosynthetic step (similarly as in AOase) is re-used to acetylate GLU in the first committed step (similarly as in NAGS) of the pathway (Figure [1](#Fig1){ref-type="fig"}B). The OATase involved in the recycling step is either monofunctional or bifunctional depending on the species. For example, the OATase from *G. stearothermophilus* \[[@CR37]\] and *N. gonorrhoeae* \[[@CR40]\] is bifunctional and accepts both Ac-CoA and Ac-ORN as substrates to acetylate GLU, whereas that from *S. coelicolor* only accepts Ac-ORN as a substrate and considered monofunctional \[[@CR46]\]. However, many of monofunctional OATases are mislabeled as bifunctional and some are still being corrected \[[@CR48]\]. For example, the OATase from *C. glutamicum* which had been known to be bifunctional for decades \[[@CR19]\],\[[@CR47]\],\[[@CR49]\]-\[[@CR51]\] has been re-considered as monofunctional \[[@CR52]\]-\[[@CR54]\], while that from *C. crenatum* remains bifunctional \[[@CR34]\]. For species such as *S. coelicolor*, the OATase is characterized. However, NAGS has not been identified in this bacterium, while new classes of NAGS are continuously being discovered for other species \[[@CR53]\]. For example, the novel type of NAGS (C-NAGS) \[[@CR53]\] encoded by *cg3035* from *C. glutamicum* adds to the diversity of NAGS including (1) the classical NAGS (as in the linear pathway), (2) the bifunctional OATase (as in the recycling pathway), (3) ArgH(A) fusion types (*argH*-*argA* fusion) \[[@CR55]\], and (4) the short versions of NAGS (S-NAGS) \[[@CR56]\]. Additionally, for species that have both NAGS and OATase such as *G. stearothermophilus* \[[@CR43]\] and *N. gonorrhoeae* \[[@CR57]\], there is a functional redundancy and the NAGS function is regarded as anaplerotic to replenish Ac-GLU \[[@CR57]\],\[[@CR58]\]. Moreover, another distinctive feature of this pathway is that NAGK reaction instead of NAGS reaction is negatively regulated by ARG \[[@CR44]\],\[[@CR52]\],\[[@CR59]\],\[[@CR60]\].

In the newly discovered pathway (Figure [1](#Fig1){ref-type="fig"}C), AOTCase from *Xanthomonas campestris* transfers carbamoyl group from carbamoyl phosphate to Ac-ORN to form Ac-CIT \[[@CR38]\]. Here, the formation of ORN is bypassed and ArgE deacetylates Ac-CIT to yield CIT. While the details of this pathway, as with the linear and recycling pathways, have not been fully explored, *C. glutamicum* and its related species with the recycling pathway are recognized as the organisms to most efficiently produce ARG.

In terms of the chromosomal genetic organization, ARG biosynthetic genes are diversely organized in different species, and that from *C. glutamicum* has been studied the most. In *C. glutamicum*, the *argCJBDFRGH* cluster is organized into two operons (*argCJBDFR* and *argGH*) \[[@CR52]\] and transcription of these operons are regulated by ARG \[[@CR61]\], ArgR \[[@CR62]\] and FarR \[[@CR63]\], while the putative *argA* (*cg3035*, encoding C-NAGS) is separated from this cluster \[[@CR32]\],\[[@CR52]\],\[[@CR53]\]. FarR regulates transcription of the *arg* operon by binding to the upstream of *argC*, *argB*, *argF* and *argG* genes \[[@CR63]\],\[[@CR64]\]. FarR additionally controls the ARG biosynthesis by binding to the upstream of the *gdh* gene encoding glutamate dehydrogenase which converts *α*-ketoglutarate (*α*-KG) into GLU \[[@CR63]\]. Similarly, ArgR, a global regulator, binds to *argC* and *argG* promoters to control ARG biosynthesis \[[@CR49]\] and the degree of down-regulation is increased by ARG \[[@CR61]\] but its binding affinity decreases by L-proline (PRO), which can be considered as a stimulator for ARG biosynthesis \[[@CR65]\]. Additionally, other strains have different chromosomal organization in the ARG operon. For example, it is partially clustered in the order of *argCJBD* in the chromosome for gram-positive bacteria such as *G. stearothermophilus* and *S. coelicolor* \[[@CR46]\],\[[@CR66]\], while the bipolar organization of *argECBH* is found in gram-negative bacteria such as *E. coli* \[[@CR67]\]-\[[@CR70]\].

Metabolic engineering for L-arginine production {#Sec3}
-----------------------------------------------

Initial approach to produce ARG at industrial scale began with random mutagenesis of microorganisms (Table [1](#Tab1){ref-type="table"}). Mutants selected based on their resistance to antimetabolites and other analogues such as canavanine (CVN) \[[@CR40]\],\[[@CR71]\], homoarginine \[[@CR72]\], arginine hydroxamate (AHX) \[[@CR18]\],\[[@CR73]\], 6-azauracil (6 AU) \[[@CR74]\], 2-thiazolealanine (TA) \[[@CR75]\], and sulfaguanine (SG) \[[@CR75]\] have been used in early attempts to overproduce ARG. Mutations were induced by radiation \[[@CR75]\],\[[@CR76]\] or treatment with mutagen such as *N*-methyl-*N*'-nitro-*N*-nitrosoguanidine (NTG) \[[@CR18]\],\[[@CR75]\]. The rational for this is to confer higher tolerance of ARG to microorganisms and to remove feedback inhibition by ARG \[[@CR9]\]. Historically, the random mutation approach had been used in various prokaryotic and eukaryotic strains including *B. subtilis* \[[@CR18]\],\[[@CR73]\],\[[@CR74]\], *Serratia marcescens* \[[@CR73]\], *Micrococcus sodonensis* \[[@CR73]\], *Norcadia corynebacteroides* \[[@CR73]\], *N. rubra* \[[@CR73]\], *Saccharomyces cerevisiae* \[[@CR73]\], *Candida tropicalis* \[[@CR73]\]*, C. glutamicum* \[[@CR72]\], *C. crenatum* \[[@CR76]\], *Brevibacterium flavum* \[[@CR75]\], *B. ketoglutamicum* \[[@CR75]\], *C. lilium* \[[@CR75]\], *Arthrobacter paraffineus* \[[@CR75]\] and *Microbacterium ammoniaphilum* \[[@CR73]\],\[[@CR75]\] to produce ARG. The trend later shifted toward using GLU overproducing *C. glutamicum* strain and its related species *C. crenatum* as base strains, which led to industrial level ARG titers. More importantly, the random mutation method is now used in synergistic combination with high-throughput molecular tools which enables systems metabolic engineering for industrial microbial strain development.Table 1**ARG, ORN, putrescine and cyanophycin producing strains**ProductYearStrain (vector if any)RemarkTiter (g/liter)ReferenceARG1971AHr-5AHX resistant *B. subtilis*; test tube culture4.5\[[@CR18]\]1973AJ 3351*B. ketoglutamicum* ATCC 15587 mutant; SG^R^,2.1\[[@CR75]\]AJ 3352*A. paraffineus* ATCC 19065 mutant; TA^R^,1.2AJ 3353*M. ammoniaphilum* ATCC 15354 mutant; TA^R^,2.9No. 348*C. lilium* NRRL B-2243 mutant; TA^R^1.8No. 352*B. flavum* ATCC 14067 mutant; guanine auxotroph; TA^R^34.81977AAr-9*B. subtilis* OUT 8103 mutant; 6AU^R^28.0\[[@CR74]\]1981KY7690*B. subtilis* ATCC 15244 mutant; AHX^R^, 5HUR^R^, TRA^R^, 6FTP^R^, 6AU^R^, 2TU^R^; 5 liter bioreactor14.0\[[@CR73]\]*S. marcescens*IFO 3046 mutant; AHX^R^, NIM^R^; test tube culture0.6*M. ammoniaphilum*ATCC 15354 mutant; AHX^R^; test tube culture0.5*M. sodonensis*ATCC 11880 mutant; AHX^R^; test tube culture4.0*N. corynebacteroides*ATCC 14898 mutant; CVN^R^; test tube culture2.5*N. rubra*NRRL 11094 mutant; AHX^R^; test tube culture8.02009RBid*C. glutamicum* ATCC 13032, *ΔargR*, A26V/M31V in ArgB; 5 liter bioreactor52.0\[[@CR47]\]2009SYPA 5-5*C. crenatum* mutant; optimization of two-stage oxygen supply strategy; 5 liter bioreactor36.6\[[@CR76]\]2011SYPA 5--5 (pJC-*tac*-*vgb*)*C. crenatum* mutant, vector-based overexpression of *vgb* from *Vitreoscilla*35.9\[[@CR77]\]2011SYPA 5--5 (pJC*tac*-*argJ*)*C. crenatum* mutant, vector-based overexpression of *argJ*; 5 liter bioreactor42.4\[[@CR34]\]2012SYPA-9039 (pJC-9039)*C. crenatum* SYPA5-5 harboring with vector-based overexpression of *argCJBDFRGH*; 5 liter bioreactor45.3\[[@CR78]\]2014AR6*C. glutamicum* ATCC 21831; AHX^R^, CVN^R^, *ΔargR*, *ΔfarR*, *pgi* (A1G), *Psod::tkt, tal, zwf, opcA, pgl, ΔNCgl1221*, *Psod::carAB*, *Petfu::argGH*; 5 liter bioreactor92.5\[[@CR9]\]Same as above except 1,500 liter bioreactor81.2ORN1996BK533*B. ketoglutamicum* ATCC 21092 derived mutant; UV and NTG treatment; 2 liter bioreactor5.7\[[@CR79]\]2008SJ8074 (pEK-CJBD)*C. glutamicum* ATCC 13032 *ΔargF*, *ΔargR, ΔproB,* vector-based overexpression of *argCJBD*0.179\[[@CR80]\]2010SJ8074 (pEK-P~trc~::1469)*C. glutamicum* ATCC 13032 *ΔargF*, *ΔargR, ΔproB,* vector-based overexpression of *NCgl1469*0.320\[[@CR54]\]2010*C. glutamicum*ATCC 13032; proline supplement3.295\[[@CR62]\]2011ORN1 (pVWEx1-*araBAD*)*C. glutamicum* ATCC 13032 *ΔargF*, *ΔargR*, vector-based overexpression of *araBAD*; optimal ARG supplement, arabinose supplement25.77\[[@CR81]\]2012*C. glutamicum*ATCC 13032 *ΔargF*, *ΔproB, Δkgd*4.78\[[@CR82]\]2012SJC8399*C. glutamicum* ATCC *ΔargF*, *ΔargR*, *ΔNcgl2399*, *ΔNcgl2905*13.16\[[@CR83]\]2013*Δ*APRE::*rocGC. glutamicum* ATCC 13032 *ΔargF*, *ΔproB*, *ΔargR, ΔspeE::*P~*tac*-*M*~-*rocG*14.84\[[@CR84]\]2013*Δ*APE6937R42*C. glutamicum* ATCC 13032 *ΔargF*, *ΔproB*, *ΔspeE*, *ΔargR*; 70 passages of adaptive evolution24.1\[[@CR85]\]2014YW6 (pSY233)*C. glutamicum* ATCC 13032 *ΔproB*, *ΔargF*, *ΔargR*, pgi^GTG^, zwf^ATG^, *Ptkt*::*Psod*, vector-based overexpression of *argCJBD* from *C. glutamicum* ATCC 21831; 5 liter bioreactor51.5\[[@CR86]\]Putrescine2009XQ52 (p15SpeC)*E. coli* W3110 *ΔlacI, ΔspeE, ΔspeG, ΔargI, ΔpuuPA,* P*argECBH*::P*trc*, P*speF*-*potE*::P*trc,* P*argD*::P*trc,* P*speC*::P*trc*, *ΔrpoS*, vector-based overexpression of *speC*; 5 liter bioreactor24.2\[[@CR28]\]2010ORN1 (pVWEx1-*speC*)*C. glutamicum* ATCC 13032 *ΔargF*, *ΔargR*, vector-based overexpression of *speC* from *E. coli* MG1655; ARG supplement,6.0\[[@CR50]\]2012ORN1 (pVWEx1-*speC*-*5*'~*21*~-*argF*)*C. glutamicum* ATCC 13032 *ΔargF*, *ΔargR*, vector-based overexpression of *speC* from *E. coli* MG1655; ARG auxotrophy rescue by fine-tuned *argF* expression *via* plasmid-addiction system19.0\[[@CR51]\]2013ORN1 (pVWEx1-*speC*-*5*'~*21*~-*argF*)*C. glutamicum* ATCC 13032 *ΔargF*, *ΔargR*, vector-based overexpression of *speC* from *E. coli* MG1655; glycerol and glucose as carbon source; ARG supplement0.855\[[@CR87]\]Cyanophycin2001*C. glutamicum* (pEK0::*cphA*)ATCC 13032, vector-based overexpression of *cphA* from *Synechocystis* sp. Strain PCC63083.6\[[@CR88]\]H16-PHB^−^4 (pBBR1::*cphA*)*R. eutropha* DSM 541 (DSM 428 derivative), PHA synthesis defect, vector-based overexpression of *cphA* from *Synechocystis* sp. Strain PCC63088.7*E. coli* (pSK::*cphA*)TOP 10, vector-based overexpression of *cphA* from *Synechocystis* sp. Strain PCC630826.0*P. putida* (pBBR1::*cphA*)KT2440, vector-based overexpression of *cphA* from *Synechocystis* sp. Strain PCC630811.02002*E. coli* (pMa/c5-914::*cphA*)DH1 strain, vector-based overexpression of *cphA* from *Synechocystis* sp. PCC6803; 30 liter bioreactor24.0\[[@CR89]\]Same as above except 500 liter bioreactor21.02004*E. coli* (pSK::*cphA1* ~7120~)TOP 10, vector-based overexpression of *cphA1* from *Anabaena* sp. strain PCC712021.0\[[@CR90]\]GPp104 (pBBR1MCS-2::*cphA1* ~7120~)*P. putida* KT2440 mutant, vector-based overexpression of *cphA1* from *Anabaena* sp. strain PCC712024.0H16-PHB^−^4 (pBBR1MCS-2::*cphA1* ~7120~)*R. eutropha* DSM 541 (DSM 428 derivative), PHA synthesis defect, vector-based overexpression of *cphA1* from *Anabaena* sp. strain PCC712022.02005*A. calcoaceticus*ATCC 33305, flask cultivation; ARG supplement46.0\[[@CR91]\]2006*R. eutropha* (pBBR1MCS-2::*cphA/eda*)DSM 541 derivative, H16-PHB^−^4 *Δeda*, vector-based overexpression of *cphA* from *Synechocystis* sp. Strain PCC6308; *eda*-dependent plasmid-addiction system; flask cultivation40.0\[[@CR92]\]Same as above except 30 liter bioreactor35.8Same as above except 500 liter bioreactor32.02011*E. coli* (pCOLADuet-1::*cphA*C595S::*dapL* ~Ss~)HMS174(DE3) *ΔdapE*, plasmid-addiction system using *dapL* from *Synechocystis* sp. Strain PCC6308, C595S mutant *cphA* from *Synechocystis* sp. Strain PCC6308; flask cultivation42.0\[[@CR93]\]Same as above except 25 liter bioreactor14.1Same as above except 400 liter bioreactor18.02012*R. eutropha* (pBBR1MCS-2::*cphA* ~6308~ */eda* ~H16~)DSM 428 mutant, H16-PHB^−^4 *Δeda*, vector-based overexpression of *cphA* from *Synechocystis* sp. Strain PCC6308, *eda*-dependent plasmid-addiction system; 30 liter bioreactor47.5\[[@CR94]\]Strains that have been reported to produce ARG, ORN, putrescine and cyanophycin are listed in the order of year for each compound. The relevant genetic information and production titers are shown. All cyanophycin production titers are given in a different unit scale (w/w %) than the rest which are given in g/liter. 5HUR, 5-hydroxyuridine; TRA, triazolealanine; 6FTP, 6-fluorotryptophan; 2TU, 2-thiouracil; 5FU, 5-fluorouracil; NIM, polyoxyethylene stearylamine.

The strategies for rationally designing ARG overproducer typically consist of (1) removal of feedback inhibition, (2) overexpression of the biosynthetic genes (e.g., the *arg* operon) and/or removal of the repressors (e.g., *argR* and *farR*), (3) increasing NADPH pool required for ARG biosynthesis, (4) increasing carbamoyl phosphate pool by overexpression of *carAB* operon and (5) deletion of exporter for GLU encoded by *NCgl1221*. For example, reverse engineering approach was taken to the wild-type *C. glutamicum* ATCC 13032 strain for deleting *argR* and introducing A26V and M31V mutations in ArgB in order to alleviate feedback inhibition \[[@CR47]\]. This is an important study because it presented the first genetically defined and not randomly mutated strain for ARG production and the engineered strain produced 52 g/liter of ARG \[[@CR47]\]. Plasmid-based engineering system has also been explored. Overexpression of a bacterial hemoglobin from *Vitreoscilla* in *C. crenatum* SYPA 5*--*5 for increased dissolved oxygen availability led to the production of 35.9 g/liter ARG \[[@CR77]\]. Plasmid-based overexpression of the *argCJBDFRGH* cluster or *argJ* alone in *C. crenatum* SYPA 5*--*5 also led to enhanced ARG production, reaching 45.3 g/liter or 42.4 g/liter, respectively \[[@CR34]\],\[[@CR78]\]. A possible explanation for little difference in ARG titer here despite the different number of gene overexpression is probably because different cultivation conditions were used (e.g., different temperatures).

Along the same line, a recent systems metabolic engineering study led to a very successful production of ARG at the industrial-scale \[[@CR9]\]. *C. glutamicum* ATCC 21831 was initially treated with CVN and AHX in order to increase its ARG tolerance and subjected to stepwise strain development. The *argR* and *farR* genes were deleted in order to relieve negative regulation on ARG biosynthesis. Next, in order to improve the NADPH pool, the pentose phosphate pathway (PPP) flux was enhanced by reducing the *pgi* expression through replacing ATG start codon with GTG, and overexpressing the major PPP operon consisting the *tkt, tal, zwf, opcA* and *pgl* by replacing the native promoter with the strong *sod* promoter. Finally the promoters for *carAB* and *argGH* operons were also changed in order to optimize fluxes toward the ARG biosynthesis and the *Ncgl1221* gene*,* encoding the GLU exporter, was deleted. As a result, the final constructed strain produced 92.5 g/liter and 81.2 g/liter of ARG at the laboratory-scale and at the industrial-scale fermentations, respectively \[[@CR9]\]. This work is a good example of systems metabolic engineering for developing a microbial strain capable of overproducing ARG to the level and performance suitable for industrial-scale production.

Metabolic engineering for L-ornithine production {#Sec4}
------------------------------------------------

The ARG-derivative, ORN, has also been produced by microbial fermentation. Both the strategies of random mutagenesis \[[@CR79]\] and systems metabolic engineering have been employed for developing strains (Figure [2](#Fig2){ref-type="fig"}). In rationally designing an ORN producer, knocking out the competing branches to redirect carbon flux to ORN pathway is an important and common strategy. Specifically, the strategies of PRO supplement \[[@CR62]\], ARG supplement \[[@CR81]\], vector-based overexpression of *argCJBD* \[[@CR80]\], *NCgl1469* overexpression \[[@CR54]\], overexpression of *rocG* from *B. subtilis* \[[@CR84]\], *ΔargF* \[[@CR80]\]-\[[@CR85]\], *ΔproB* \[[@CR82]\],\[[@CR84]\],\[[@CR85]\], *ΔspeE* \[[@CR84]\],\[[@CR85]\], *ΔargR* \[[@CR81]\],\[[@CR83]\]-\[[@CR85]\], *ΔNCgl2399* \[[@CR83]\]*, ΔNCgl2905* \[[@CR83]\], and *Δkgd* \[[@CR82]\] have been employed for developing strains for ORN overproduction (Table [1](#Tab1){ref-type="table"}).Figure 2**Systems metabolic engineering strategies.** The metabolic engineering strategies used for the construction of microbial strains producing ARG, ORN, putrescine and cyanophycin are shown. Increased and decreased gene expression levels are shown in green and orange arrows. Purple arrows indicate reactions carried out by chemical means. The *pgi* encodes phosphoglucose isomerase, *zwf* encodes glucose-6-phosphate dehydrogenase, *pgl* encodes 6-phosphogluoconolactonase, *gnd* encodes 6-phosphogluconate dehydrogenase, *tkt* encodes transketolase and *tal* encodes transaldolase. Gene deletion is indicated with red crosses. GABA, gamma-aminobutyrate; Ac-putrescine, acetyl-putrescine; G6P, glucose-6-phosphate; F6P, fructose-6-phosphate; F1,6P, fructose-1,6-bisphosphate; 6PGL, 6-phosphogluconolactone; 6PG, 6-phosphogluconate; Ru5P, ribulose-5-phosphate; R5P, ribose-5-phosphate; G3P, glyceraldehyde-3-phosphate; X5P, xylulose-5-phosphate; S7P, sedoheptulose-7-phosphate; E4P, erythrose-4-phosphate; A, ARG; O, ORN; P, putrescine.

The strategies for the development of ORN producers are similar to those employed for ARG producers except auxotrophy rescue by supplements is additionally used. Here, *ΔargF* and *ΔproB* are often included in order to disrupt OTCase and gamma-glutamyl kinase, respectively \[[@CR80]\]-\[[@CR85]\]. Although this strategy leads to higher ORN titer, it makes the strain auxotrophic for ARG and PRO since their biosynthesis is disrupted \[[@CR62]\],\[[@CR81]\]. Another common strategies are deletion of the repressor (*ΔargR*) \[[@CR81]\],\[[@CR83]\]-\[[@CR85]\] as in ARG strain cases, and overexpression of the biosynthetic genes (e.g., *argCJBD*) using plasmids \[[@CR80]\]. Overexpression of putative biosynthetic genes can also be a strategy for ORN production. It has been reported that overexpression of putative NAGS encoded by *NCgl1469* leads to increased ORN production \[[@CR54]\] while others claim *Ncgl1469* as diaminopentane acetyltransferase \[[@CR95]\]. It is possible that *Ncgl1469* potentially encodes a broad-substrate acetyltransferase that has not been characterized in detail. The TCA cycle flux can also be reduced by deleting 2-oxoglutarate dehydrogenase complex (ODHC) for the enhanced production of ORN \[[@CR82]\].

Increasing the NADPH pool also improves ORN production. The use of *B. subtilis rocG* which encodes NAD-dependent glutamate dehydrogenase allows conversion of *α*-KG to GLU in an NADPH-independent manner and leaves more NADPH for ORN biosynthesis \[[@CR84]\]. Increasing the NADPH level can also be achieved by inactivating two putative gluconate kinases (*gntK*) encoded by *NCgl2399* and *NCgl2905* \[[@CR83]\]. Overexpression of the ATP-dependent NAD kinase encoded by *ppnK* also leads to enhanced ORN production, while overexpression of glucose-6-phosphate dehydrogenase encoded by *zwf* and 6-phosphogluconate dehydrogenase encoded by *gnd* does not do the same \[[@CR85]\]. A possible explanation is that plasmid-based overexpression of *zwf* and *gnd* causes cellular burdens because chromosomal-level overexpression has shown improvement in ORN titer \[[@CR86]\]. An indirectly associated pathway for spermidine biosynthesis can also be deleted for enhanced ORN production, yet the reason behind it has not been explained \[[@CR85]\]. Combining the aforementioned strategies, a recently developed strain was reported to produce 51.5 g/L of ORN \[[@CR86]\]. In this strain, the PPP flux was enhanced by changing the *tkt* promoter and the start codons of *pgi* and *zwf*. The *argCJBD* cluster from *C. glutamicum* ATCC 21831 was overexpressed and *argF*, *proB* and *argR* were deleted.

Metabolic engineering for putrescine production {#Sec5}
-----------------------------------------------

Putrescine (1,4-diaminobutane) can be produced by metabolic engineering of ARG related pathways. The major chassis organisms that have been employed are *E. coli* \[[@CR28]\] and *C. glutamicum* \[[@CR50]\]. While the putrescine biosynthesis pathway is not well known in *C. glutamicum,* it is a desirable host as it produces ORN efficiently and tolerates putrescine better than *E. coli* \[[@CR28]\],\[[@CR50]\]. Although putrescine biosynthesis can be alternatively achieved *via* agmatine pathway (Figure [2](#Fig2){ref-type="fig"}), the ODC pathway was shown to be more efficient than the agmatine pathway \[[@CR50]\]. In addition to the strategies employed for developing ARG and ORN producers described in prior sections, engineering the transporters are the additional strategies for designing cell-factories for putrescine production.

Putrescine can be synthesized from ORN by a single reaction carried out by ornithine decarboxylase (ODC) encoded by *speC* (Figure [2](#Fig2){ref-type="fig"}). The ODC from *E. coli* is often used since the metabolic pathway in *C. glutamicum* for putrescine has not been identified \[[@CR50]\]. To develop a putrescine producing *C. glutamicum* strain, the arginine repressor encoded by *argR* should be inactivated as in the ARG and ORN overproducing strains \[[@CR50]\],\[[@CR51]\]. While disruption of OTCase is also a strategy for improving ORN pool, this makes the strain to become an ARG auxotroph \[[@CR50]\]. Here, the ARG auxotrophy caused by *ΔargF* can be overcome by introducing a plasmid expressing *argF* which is also fine-tuned \[[@CR51]\]. The use of this strategy is an example of plasmid-addiction system and it circumvents the undesirable use of antibiotic as well because cell viability becomes plasmid-dependent \[[@CR96]\]. While engineering of the putrescine transport system in *C. glutamicum* would further enhance its production, this strategy has yet been applied only in *E. coli* \[[@CR28]\]. Along with the overexpression of putrescine/ornithine antiporter (encoded by *potE*) and deletion of putrescine importer (encoded by *puuP*), the competitive and degradation routes were deleted in the putrescine producing *E. coli* XQ52 strain \[[@CR28]\]. Chromosomal deletion of *puuA* encoding glutamate-putrescine ligase, *speE* encoding spermidine synthase, *speG* encoding spermidine acetyltransferase, and *argI* encoding one of the monomers for OTCase improved putrescine production. The native promoters of the key biosynthetic genes (*argECBH* operon, *argD* and *speC*) were changed to stronger promoters and the repressor *argR* was deleted. The *rpoS* gene encoding the stress-responsive RNA polymerase sigma factor was also deleted, which led to the development of the final strain capable of producing 24.2 g/liter of putrescine \[[@CR28]\]. While the highest putrescine producing strain reported is so far *E. coli*, further engineering of ORN overproducing *C. glutamicum* strain will likely led to the development of a more efficient putrescine producer due to its high-tolerance to putrescine \[[@CR86]\].

Metabolic engineering for cyanophycin production {#Sec6}
------------------------------------------------

Cyanophycin was first discovered more than a century ago in cyanobacteria as a carbon and nitrogen storage compound \[[@CR97]\]. Cyanophycin has been recently attracting attention because it can be chemically reduced to make polyaspartate. Polyaspartate is a completely biodegradable polymer \[[@CR88]\], which can be used as a polyacrylate substitute, an additive polymer in the oil field \[[@CR98]\], and as a polymer suitable for water treatments and medical applications \[[@CR99]\]. Additionally, cyanophycin can also be used to produce isotope-labeled ARG \[[@CR100]\].

Cyanophycin is composed of equimolar amount of ARG and L-aspartate (ASP). Cyanophycin synthetase encoded by *cphA* carries out the reaction of polymerizing ASP and ARG (Figure [2](#Fig2){ref-type="fig"}). Various strains including *P. putida* \[[@CR88]\],\[[@CR90]\], *R. eutropha* \[[@CR88]\],\[[@CR92]\],\[[@CR94]\], *C. glutamicum* \[[@CR88]\] and *E. coli* \[[@CR88]\],\[[@CR89]\],\[[@CR93]\] have been employed for the production of cyanophycin through the heterologous expression of *cphA* from *Synechocystis* sp. PCC6803 \[[@CR89]\] or *Anabaena* sp. strain PCC7120 \[[@CR90]\]. *Acinetobacter calcoaceticus* \[[@CR91]\],\[[@CR101]\] has also been used to produce cyanophycin using the endogenous *cphA* gene \[[@CR91]\],\[[@CR101]\]. The metabolic engineering strategies employed include the use of mutants incapable of accumulating polyhydroxyalkanoates \[[@CR88]\],\[[@CR92]\],\[[@CR94]\], plasmid-addiction system using *eda* \[[@CR92]\],\[[@CR94]\] or *dapE* \[[@CR93]\] deleted strains, and the use of CphA variant having C595S mutation \[[@CR102]\]. There was an interesting report on the use of 2-keto-3-deoxy-6-phosphogluconate aldolase encoded by *eda,* which is required in gluconate and fructose metabolism. The use of this gene for plasmid-addiction system in *Δeda* strain circumvents the need to use antibiotics in large-scale cultivation. The 30, 400 and 500 liter-scale bioreactors have been used for the large-scale production of cyanophycin, which was followed by successful purification; at the end, the titer corresponding to 750 g of cyanophycin with 75% extraction yield have been reported \[[@CR89]\].

Conclusions {#Sec7}
===========

With increasing volumes of biological information and availability of high-throughput molecular tools, systems metabolic engineering has become an essential strategy for developing microbial strains overproducing ARG, ORN, putrescine and cyanophycin. Systems metabolic engineering obviously requires thorough understanding of the metabolism and gene regulatory circuits towards the production of desired products. The strategies of knocking out the negative regulatory mechanisms, amplifying the fluxes of pathways towards the product formation, deleting the byproducts forming pathways, and increasing the exporters while reducing the importers have been combined to develop microbial strains capable of producing ARG and related products. Such engineering strategies have been successfully applied to rationally construct a high-performance strain which works efficiently not only at the laboratory-scale but also at the semi industrial-scale fermentation. New tools of systems metabolic engineering are continuously emerging. For example, further metabolic engineering of the strain based on the sRNA technology can be envisioned to rapidly develop high-level producers. The strategies described here will be useful for developing microbial strains capable of more efficiently producing ARG and related products, including not only those mentioned in this paper but also other derivatives including sarcosine, creatine, agmatine and creatinine.
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ARG

:   L-arginine

LYS

:   L-lysine

TRP

:   L-tryptophan

VAL

:   L-valine

THR

:   L-threonine

ALA

:   L-alanine

ASP

:   L-aspartate

ORN

:   L-ornithine

PRO

:   L-proline

CIT

:   L-citrulline

GLU

:   L-glutamate

Ac-ORN

:   *N*-acetylornithine

Ac-CIT

:   *N*-acetylcitrulline

Ac-CoA

:   Acetyl coenzyme A

*α*-KG

:   *α*-ketoglutarate

OATase

:   Ornithine acetyltransferase

OTCase

:   Ornithine cabamoyltransferase

NAGS

:   *N*-acetylglutamate synthase

NAGK

:   *N*-acetylglutamate kinase

AOase

:   Acetylornithinase

AOTCase

:   Acetylornithine carbamoyltransferase

ODC

:   Ornithine decarboxylase

PPP

:   Pentose phosphate pathway

AHX

:   Arginine hydroxamate

CVN

:   Canavanine

6 AU

:   6-azauracil

TA

:   2-thiazolealanine

SG

:   Sulfaguanine

NTG

:   *N*-methyl-*N*'-nitro-*N*-nitrosoguanidine

NADPH

:   Nicotinamide adenine dinucleotide phosphate

ATP

:   Adenosine triphosphate
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